Phase 2 Mesothelioma Trial, Recruiting NCT06503146 Sponsor: National Cancer Institute (NCI) Condition: Mesothelioma
Back to Mesothelioma

Phase 2 Mesothelioma Trial, Recruiting

NCT06503146
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with one of the following cancers (confirmed by a tissue sample/biopsy): pancreatic cancer, bile duct cancer (cholangiocarcinoma), liver cancer (hepatocellular carcinoma), stomach cancer, bladder cancer, ovarian cancer, a tumor of the adrenal gland or nearby nerve tissue (pheochromocytoma/paraganglioma), small cell lung cancer, a type of neuroendocrine cancer outside the lungs, mesothelioma, or sarcoma.
  • You are scheduled or planned to receive treatment for your cancer.
  • Your cancer can be detected and measured through testing.
  • You are 18 years of age or older.
  • You are well enough to carry out some daily activities, with only limited difficulty (confirm with trial site regarding the specific fitness scale used).
  • If you are able to become pregnant or father a child, you must agree to use effective birth control (such as condoms, hormonal methods, an IUD, surgical sterilization, or abstinence) from the start of the study until 2 months after each imaging scan, and you must not freeze or donate sperm during that time.
  • If you are currently breastfeeding, you must be willing to stop breastfeeding for 2 months after each study imaging scan.
  • You are able to understand the study and are willing to sign a consent form agreeing to take part.

Who may not be able to join:

  • You have a history of serious allergic reactions to substances chemically similar to the imaging agent used in this study (called [18F]FAPI-74) or to other agents used in the study.
  • You have severe claustrophobia (fear of enclosed spaces) that cannot be managed with oral medication, or any other condition that would prevent you from lying still in a scanning machine for up to 45 minutes.
  • You weigh more than 350 lbs., or you are unable to fit inside the imaging scanner.
  • You are pregnant (confirmed by a blood or urine pregnancy test at the start of the study).
  • You have another serious, uncontrolled illness — such as kidney failure, liver failure, or a mental health condition — that could make it difficult to follow the study requirements or could put you at additional risk.
  • Your kidney function is significantly reduced, based on a specific blood test result (confirm with trial site for exact values).
  • Your liver enzyme levels are significantly elevated, based on a specific blood test result (confirm with trial site for exact values).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Esther Mena Gonzalez, M.D., National Cancer Institute (NCI)

Phone: (240) 760-6095

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
9 September 2025
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Mean number of lesions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov